

CROI 2022 Schedule at a Glance

February 12-16 (with symposia on February 22, 23, and 24)

Live Program • February 12 – 16, 2022

Time	Saturday, February 12, 2022	Sunday, February 13, 2022	Monday, February 14, 2022	Tuesday, February 15, 2022	Wednesday, February 16, 2022	
8:30 AM MT START	W-1 SCOTT M. HAMMER WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES (8:30 AM – 12:30 PM) <ul style="list-style-type: none">ADVANCES IN MOLECULAR VIROLOGY OF HIV AND SARS-CoV-2ADVANCES IN HIV AND SARS-CoV-2 IMMUNOLOGYADVANCES IN COVID-19 TREATMENT STRATEGIES AND CONTROLLING THE EPIDEMICADVANCES IN BIOMEDICAL PREVENTION OF HIVADVANCES IN HIV CURE WITH CLINICAL PERSPECTIVES	OPENING SESSION (8:30 – 10:45 AM) MARTIN DELANEY PRESENTATION <ul style="list-style-type: none">WE’RE STILL HERE: HIV, AGING, AND THE INVISIBLE GENERATION BERNARD FIELDS LECTURE <ul style="list-style-type: none">VACCINE STRATEGIES FOR HIV-1 AND COVID-19 N’GALY-MANN LECTURE <ul style="list-style-type: none">HIV RESEARCH: GENERATING EVIDENCE TO ADVANCE PUBLIC HEALTH POLICIES IN BRAZIL THE COVID-19 EPIDEMIC IN THE UNITED STATES: A DISCUSSION WITH DR ROCHELLE WALENSKY	P-1 MONDAY PLENARY SESSION (8:30 – 9:30 AM) <ul style="list-style-type: none">HIV NONHUMAN PRIMATE MODELS FOR STUDIES OF VIRUS PATHOGENESIS, PERSISTENCE, AND CURECHILDREN EXPOSED TO HIV, BUT UNINFECTED: EVIDENCE FOR ACTION	P-2 TUESDAY PLENARY SESSION (8:30 – 9:30 AM) <ul style="list-style-type: none">NEW INSIGHTS INTO HIV RNA BIOLOGYUNDERSTANDING THE EPIDEMIOLOGY OF COVID-19: A GLOBAL PERSPECTIVE	P-3 WEDNESDAY PLENARY SESSION (8:30 – 9:30 AM) <ul style="list-style-type: none">NEW ANTIRETROVIRALS AND THE FUTURE OF HIV TREATMENT AND PREVENTIONPAST AND FUTURE OF HIV VACCINES	
9:45 AM MT			ORAL ABSTRACT SESSIONS (9:45 – 11:45 AM) 0-1 TARGETS AND BARRIERS TO VIRAL INFECTION 0-2 MATERNAL AND CHILD HEALTH: NEW INSIGHTS INTO HEPATITIS, SARS-CoV-2, AND HIV 0-3 MALIGNANCIES AND COMORBIDITIES: AN INCREASING BURDEN 0-4 EVOLVING EPIDEMIOLOGY OF HIV AND SARS-CoV-2	ORAL ABSTRACT SESSIONS (9:45 – 11:45 AM) 0-5 HIV RESERVOIRS AND CURE STRATEGIES 0-6 TUBERCULOSIS, OPPORTUNISTIC INFECTIONS, AND HEPATITIS 0-7 HIV PREVENTION: FROM THE BENCH TO POPULATION 0-8 GLOBAL PERSPECTIVES ON HIV TESTING, TREATMENT, AND PREVENTION 0-9 SARS-CoV-2 ANTIVIRALS AND OUTCOMES	ORAL ABSTRACT SESSIONS (9:45 – 11:45 AM) 0-10 IMMUNE RESPONSES TO HIV AND SARS-CoV-2 IN TREATMENT, PREVENTION, AND PATHOGENESIS 0-11 CROSSING THE CNS BORDER: HIV, SIV, AND SARS-CoV-2 0-12 HIV ANTIVIRALS AND OUTCOMES 0-13 SHIFTING PARADIGMS IN HIV TESTING	
11:00 AM MT			CONCURRENT TECHNICAL WORKSHOPS (11:00 AM – 1:00 PM) W-2 FRONTIERS IN LABORATORY TECHNOLOGIES <ul style="list-style-type: none">POPULATION LEVEL VIRAL SEQUENCINGDEEP MUTATIONAL SCANNING TO INTERPRET VIRAL EVOLUTIONAI-INSPIRED MONOCLONAL THERAPEUTIC ANTIBODY DESIGNSINGLE-CELL PROTEOMICS W-3 CASE-BASED LIVER WORKSHOP <ul style="list-style-type: none">LIVER STEATOSIS IN PERSONS LIVING WITH HIVGETTING HEPATITIS C AGAINCONTROVERSIES IN HEPATITIS BTHE ORIGINAL DELTA VIRUS OR D LIKE THE DEVIL W-4 CLINICAL TRIAL DESIGN AND ANALYSIS <ul style="list-style-type: none">STUDYING COVID TREATMENT OUTCOMES: WHY DISPARATE RESULTS?ANALYSIS APPROACHES TO CORRELATES OF VACCINE EFFICACYASSESSING VACCINE EFFICACY IN THE REAL WORLD	CONCURRENT INTERACTIVE SESSIONS (12:00 – 1:00 PM) I-1 VIRAL SURVIVAL STRATEGIES IN THE FACE OF HOST IMMUNE RESPONSES: IMPLICATIONS FOR VACCINES <ul style="list-style-type: none">UNIQUE CHALLENGES OF VACCINATING DURING A PANDEMICHPV VACCINE: A SUCCESSFUL MODEL OF VACCINE-INDUCED MUCOSAL ANTIVIRAL IMMUNE RESPONSEFLU VACCINES: THE GLASS HALF-FULLHERPES VIRUSES: VIRUSES THAT EVADE VACCINE-INDUCED HOST-IMMUNE RESPONSESHIV-1: THE ULTIMATE CHALLENGE FOR VACCINE DEVELOPMENT I-2 COVID-19 TREATMENT: CONSENSUS AND CONTROVERSIES I-3 (COVID-19) VACCINE MANDATES: THE PAST, THE PRESENT, AND THE WAY FORWARD <ul style="list-style-type: none">VACCINE MANDATES: HISTORY IN THE UNITED STATES AND OTHER COUNTRIESVACCINE HESITANCY AMONG MEMBERS OF RACIAL AND ETHNIC MINORITY GROUPSLEGAL AND POLITICAL ISSUES RELATED TO VACCINE MANDATES IN THE US, AND SOLUTIONS FOR OVERCOMING THEM	CONCURRENT INTERACTIVE SESSIONS (12:00 – 1:00 PM) I-4 LONG COVID: FROM BENCH TO BEDSIDE AND BEYOND <ul style="list-style-type: none">PUTTING LONG COVID IN CONTEXTTHEMES IN NEUROLOGYTHEMES IN VIROLOGYTHEMES IN IMMUNOLOGY I-5 WHAT WILL IT TAKE TO INCREASE PEP AND PrEP USE FOR ADOLESCENT GIRLS AND YOUNG WOMEN AT RISK? <ul style="list-style-type: none">GLOBAL PrEP UPTAKE IN ADOLESCENT GIRLS AND YOUNG WOMENEXPERIENCE WITH OFFERING PEP ALONGSIDE PrEPPrEP IMPLEMENTATION IN ADOLESCENT GIRLS AND YOUNG WOMENPrEP IMPLEMENTATION IN YOUNG SEX WORKERS IN ZIMBABWE	CONCURRENT INTERACTIVE SESSIONS (12:00 – 1:00 PM) I-6 CHIMERIC ANTIGEN RECEPTORS (CARs): WHAT’S NEXT? <ul style="list-style-type: none">NEW AND IMPROVED T CELL CARs FOR HIV ERADICATION OR CONTROLGENERATING CAR T CELLS IN VIVONATURAL KILLER CELL CARs: NEW APPROACHES TO CURE LEUKEMIA AND LYMPHOMASTIMULATING CARs WITH mRNA VACCINES I-7 HIV CONTROVERSIES: CASE-BASED APPROACH TO PATIENTS WHO ARE TREATMENT OR PREVENTION EXPERIENCED I-8 IMPACT OF VIRAL LOAD IN TRANSMISSION AND DISEASE PROGRESSION OF SARS-CoV-2 INFECTION <ul style="list-style-type: none">ROLE OF VARIANTS AND VIRAL LOAD IN SARS-CoV-2 TRANSMISSIONIS SARS-CoV-2 VIRAL LOAD ASSOCIATED WITH DISEASE PROGRESSION AND RESPONSE TO TREATMENT?ARE NEW SARS-CoV-2 VARIANTS ASSOCIATED WITH MORE SEVERE DISEASE?VIRAL LOAD KINETICS IN PARTIALLY OR FULLY VACCINATED INDIVIDUALS INFECTED WITH SARS-CoV-2
12:00 PM MT						
12:30 PM MT						
1:00 PM MT						
1:15 PM MT			NETWORKING SESSIONS FOR NEW INVESTIGATORS (1:15 – 1:55 PM)	NETWORKING SESSIONS FOR NEW INVESTIGATORS (1:15 – 1:55 PM) SPECIAL SESSION: ANAL CANCER PREVENTION AND MANAGEMENT (1:15 – 2:00 PM)	NETWORKING SESSIONS FOR NEW INVESTIGATORS (1:15 – 1:55 PM)	
2:00 PM MT			LIVE CHAT SESSIONS WITH POSTER PRESENTERS (2:00 – 3:30 PM)	LIVE CHAT SESSIONS WITH POSTER PRESENTERS (2:00 – 3:30 PM)	LIVE CHAT SESSIONS WITH POSTER PRESENTERS (2:00 – 3:30 PM)	

Live Symposia Program • February 22 – 24, 2022

Time	Tuesday, February 22, 2022	Wednesday, February 23, 2022	Thursday, February 24, 2022
8:30 AM MT START	Consecutive Symposia Sessions (8:30 AM – 1:30 PM) S-1 GETTING INTO SHAPE: A DEEPER LOOK AT VIRAL MATURATION (8:30 – 10:00 AM) <ul style="list-style-type: none"> HIV-1 MATURATION – NEW VIEWS OF AN EXTRAORDINARY METAMORPHOSIS NEW ROLE FOR INTEGRASE IN VIRAL MATURATION STRUCTURE, ASSEMBLY, AND FUNCTIONAL ROLES OF THE INTASOME IN HIV REPLICATION 	Consecutive Symposia Sessions (8:30 AM – 1:30 PM) S-4 THE HIV RESERVOIR: CREATION, SELECTION, MAINTENANCE, AND REVERSAL (8:30 – 10:00 AM) <ul style="list-style-type: none"> THE HIV-1 PROVIRAL LANDSCAPE: WHAT HAVE WE LEARNED? ROLE OF SELECTION PRESSURES AND IMMUNE RESPONSES IN SHAPING THE PERSISTENT RESERVOIR NOVEL IMMUNOTHERAPY-BASED CURE INTERVENTIONS 	Consecutive Symposia Sessions (8:30 AM – 1:30 PM) S-7 IMMUNE PROTECTION IN THE FIELD: RAISING THE STAKES (8:30 – 10:00 AM) <ul style="list-style-type: none"> LESSONS LEARNED FROM THE AMP TRIAL: IS THE GLASS HALF FULL? PUSHING THE ENVELOPE: mRNA VACCINES FOR COVID-19, HIV, AND OTHER PATHOGENS JUMP-STARTED IMMUNE RESPONSE: NOW, HOW TO TEACH BREADTH?
10:15 AM MT	S-2 INFANT POSTNATAL PROPHYLAXIS: WHY BOTHER? (10:15 – 11:45 AM) <ul style="list-style-type: none"> SETTING THE STAGE: POSTNATAL PROPHYLAXIS TO REDUCE NEW PEDIATRIC INFECTIONS ANTIRETROVIRALS FOR PREVENTION: FROM ADULTS TO BABIES SPEED DIALING NEONATES TO THE IDEAL POSTNATAL PROPHYLAXIS REGIMEN 	S-5 TUBERCULOSIS: NEW STRATEGIES IN THE TREATMENT OF THE WORLD'S OLDEST EPIDEMIC (10:15 – 11:45 AM) <ul style="list-style-type: none"> TREATMENT SHORTENING FOR DRUG-SUSCEPTIBLE TB: WHERE ARE WE AND WHAT'S NEXT? A NEW ERA FOR TREATMENT OF MULTI-DRUG RESISTANT TUBERCULOSIS THE PROMISE OF NEW DRUGS AND LONG-ACTING INJECTABLES FOR TB TREATMENT AND PREVENTION 	S-8 HIV AND AGING (10:15 – 11:45 AM) <ul style="list-style-type: none"> CLINICAL EPIDEMIOLOGY OF AGING AND COMORBIDITY WITH HIV INFECTION: A GLOBAL PERSPECTIVE POTENTIAL BIOLOGIC MECHANISMS OF AGING IN HIV INTEGRATING FRAILTY AND FUNCTIONAL OUTCOMES INTO CLINICAL TRIALS
12:00 PM MT	S-3 BRINGING CHOICE TO HIV PREVENTION (12:00 – 1:30 PM) <ul style="list-style-type: none"> PREPARING FOR THE PLATE OF PREVENTION OPTIONS: HOW CAN WE DELIVER? BUILDING BACK BETTER: PUBLIC HEALTH SYSTEMS, PUBLIC TRUST, AND THE PrEP PIPELINE APPLYING LESSONS ON EFFICACY AND AUTONOMY FROM CONTRACEPTION TO PrEP 	S-6 SEXUALLY TRANSMITTED INFECTIONS: REVERSING THE TIDE (12:00 – 1:30 PM) <ul style="list-style-type: none"> THE STATE OF STI EPIDEMICS AND RESPONSE IN THE UNITED STATES CURRENT AND FUTURE RESEARCH IN STI VACCINES SEXUALLY TRANSMITTED INFECTIONS PROPHYLAXIS, IS THIS THE ANSWER? 	S-9 HIV PREVENTION IN SPECIAL POPULATIONS (12:00 – 1:30 PM) <ul style="list-style-type: none"> A COMPREHENSIVE APPROACH TO HIV PREVENTION IN PEOPLE WHO USE SUBSTANCES TAILORING HIV PREVENTION STRATEGIES FOR THE UNIQUE NEEDS OF TRANSGENDER AND NONBINARY PEOPLE HIV PREVENTION APPROACHES TAILORED TO INDIVIDUALS ENGAGED IN SEX WORK
1:30 PM MT END			